FSHD - Facioscapulohumeral Muscular Dystrophy
8
4
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
BetterLife FSHD: A Patient-driven Health and Research Platform
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)
Imaging and Gait Analysis in FSHD Patients
Muscle MRI Outlining of Neuromuscular Diseases Using Artificial Intelligence
Ten Year Follow-up in FSHD: the FOCUS 3 Study
High Intensity Training in Patients With Facioscapulohumeral Muscular Dystrophy
1 Year MRI Followup in Facioscapulohumeral Muscular Dystrophy